JANE L LIESVELD, MD
Osteopathic Medicine at Elmwood Ave, Rochester, NY
License number
New York 147702
Category
Osteopathic Medicine
Type
Hematology
License number
New York 147702
Category
Osteopathic Medicine
Type
Medical Oncology
License number
New York 147702
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
601 Elmwood Ave, Rochester, NY 14642
Phone
(585) 275-0784
(585) 273-5761 (Fax)
(585) 276-2140 (Fax)
(585) 273-5761 (Fax)
(585) 276-2140 (Fax)
Personal information
See more information about JANE L LIESVELD at radaris.comName
Address
Phone
50 Viennawood Dr, Rochester, NY 14618
601 Elmwood Ave, Rochester, NY 14620
50 Viennawood Dr, Rochester, NY 14618
Professional information
Dr. Jane L Liesveld, Rochester NY - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
UNIVERSITY OF ROCHESTER MEDICAL
601 Elmwood Ave SUITE 610, Rochester 14642
(585) 275-5863 (Phone), (585) 273-5761 (Fax)
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 2-0743, Rochester 14642
(585) 276-6389 (Phone)
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 704, Rochester 14642
(585) 275-5823 (Phone)
601 Elmwood Ave SUITE 610, Rochester 14642
(585) 275-5863 (Phone), (585) 273-5761 (Fax)
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 2-0743, Rochester 14642
(585) 276-6389 (Phone)
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 704, Rochester 14642
(585) 275-5823 (Phone)
Certifications:
Hematology, 1986, Internal Medicine, 1983, Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UNIVERSITY OF ROCHESTER MEDICAL
601 Elmwood Ave SUITE 610, Rochester 14642
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 2-0743, Rochester 14642
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 704, Rochester 14642
Highland Hospital
1000 South Ave, Rochester 14620
Strong Memorial Hospital
601 Elmwood Ave, Rochester 14642
601 Elmwood Ave SUITE 610, Rochester 14642
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 2-0743, Rochester 14642
James P Wilmot Cancer Center
601 Elmwood Ave SUITE 704, Rochester 14642
Highland Hospital
1000 South Ave, Rochester 14620
Strong Memorial Hospital
601 Elmwood Ave, Rochester 14642
Education:
Medical School
University of Ia Roy J & L Carver Com
Graduated: 1980
Strong Memorial Hospital
U Rochester-Strong Meml Hos
University of Ia Roy J & L Carver Com
Graduated: 1980
Strong Memorial Hospital
U Rochester-Strong Meml Hos
Jane L Liesveld, Rochester NY
Specialties:
Hematologist
Address:
601 Elmwood Ave, Rochester, NY 14642
Education:
University of Iowa, Roy J. and Lucille A. Carver College of Medicine - Doctor of Medicine
Strong Memorial Hospital - Fellowship - Hematology and Oncology (Internal Medicine)
Strong Memorial Hospital - Residency - Internal Medicine
Strong Memorial Hospital - Fellowship - Hematology and Oncology (Internal Medicine)
Strong Memorial Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Jane Liesveld, Rochester NY
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology, Allergy & Immunology, Hematology
Work:
Strong Memorial Hospital
601 Elmwood Ave, Rochester, NY 14642
601 Elmwood Ave, Rochester, NY 14642
Education:
University of Iowa (1980)
Thrombopoietin Mimetics For The Treatment Of Radiation Or Chemical Induced Bone Marrow Injury
US Patent:
2014004, Feb 13, 2014
Filed:
Mar 15, 2013
Appl. No.:
13/838111
Inventors:
Yuhchyau CHEN - Pittsford NY, US
Jane L. LIESVELD - Rochester NY, US
Lin GAN - Pittsford NY, US
Jane L. LIESVELD - Rochester NY, US
Lin GAN - Pittsford NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
A61K 31/4152, G01N 33/50, A61K 45/06
US Classification:
800 18, 514404, 424 937, 435355, 435 721
Abstract:
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal. The chimeric thrombopoietin receptor comprises either the transmembrane domain of a human thrombopoietin receptor or both the extracellular and transmembrane domains of a human thrombopoietin receptor operably coupled to a cytoplasmic domain of a non-human thrombopoietin receptor.
Continuous Flow Chamber Device For Separation, Concentration, And/Or Purification Of Cells
US Patent:
2006018, Aug 17, 2006
Filed:
Jan 20, 2006
Appl. No.:
11/335573
Inventors:
Michael King - Rochester NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John Gentile - Rochester NY, US
Nathan Clark - Rochester NY, US
Nipa Mody - West Henrietta NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John Gentile - Rochester NY, US
Nathan Clark - Rochester NY, US
Nipa Mody - West Henrietta NY, US
International Classification:
C12N 5/08
US Classification:
435372000
Abstract:
The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.
Continuous Flow Chamber Device For Separation, Concentration, And/Or Purification Of Cells
US Patent:
2009025, Oct 8, 2009
Filed:
Oct 17, 2008
Appl. No.:
12/289006
Inventors:
Michael R. King - Rochester NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John P. Gentile - Spencerport NY, US
Nathan Clark - Rochester NY, US
Nipa A. Mody - West Henrietta NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John P. Gentile - Spencerport NY, US
Nathan Clark - Rochester NY, US
Nipa A. Mody - West Henrietta NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
C12N 5/06
US Classification:
435395
Abstract:
The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.
Continuous Flow Chamber Device For Separation, Concentration, And/Or Purification Of Cells
US Patent:
2009002, Jan 22, 2009
Filed:
Jan 16, 2008
Appl. No.:
12/007877
Inventors:
Michael R. King - Rochester NY, US
Jane Liesveld - Rochester NY, US
Kuldeepsinh Rana - Rochester NY, US
Jane Liesveld - Rochester NY, US
Kuldeepsinh Rana - Rochester NY, US
International Classification:
A61K 9/00, C12M 1/00, C12N 5/00, A61P 35/00
US Classification:
424422, 4352831, 4353061, 435375
Abstract:
The present invention relates to methods and apparatuses for neutralizing cancer cells. In particular, the invention relates to separating of cancer cell type from a mixture of different cell types based on the differential rolling property of cancer cell on a substrate coated with a first molecules that exhibits adhesive property with the particular cell type and neutralizing the cancer cell by a second molecule that is also coated on the substrate. This technology is adaptable for use in vivo, in vitro, or ex vivo tumor neutralization.
Continuous Flow Chamber Device For Separation, Concentration, And/Or Purfication Of Cells
US Patent:
2007017, Aug 2, 2007
Filed:
Dec 4, 2006
Appl. No.:
11/607879
Inventors:
Michael King - Rochester NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John Gentile - Spencerport NY, US
Kuldeepsinh Rana - Rochester NY, US
Nathan Clark - Rochester NY, US
Nipa Mody - West Henrietta NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John Gentile - Spencerport NY, US
Kuldeepsinh Rana - Rochester NY, US
Nathan Clark - Rochester NY, US
Nipa Mody - West Henrietta NY, US
International Classification:
A61K 39/395, G01N 33/567, G01N 33/574
US Classification:
424140100, 435007210, 435007230
Abstract:
The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.
Anti-Thymocyte Antiserum And Use Thereof To Trigger B Cell Apoptosis
US Patent:
2007003, Feb 8, 2007
Filed:
Oct 22, 2004
Appl. No.:
10/576428
Inventors:
Martin Zand - Rochester NY, US
Jainulabdeen Ifthikharuddin - Rochester NY, US
Jane Liesveld - Rochester NY, US
Camille Abboud - Rochester NY, US
Jainulabdeen Ifthikharuddin - Rochester NY, US
Jane Liesveld - Rochester NY, US
Camille Abboud - Rochester NY, US
International Classification:
A61K 39/395
US Classification:
424144100, 424155100
Abstract:
Methods and products are described for inducing B cell apoptosis, using antibody-induced apoptosis. Specifically, polyclonal antiserum or one or more monoclonal antibodies, either alone or in combination, as well as fragments or variants thereof are employed in the methods and products of the present invention. These antibodies, or fragments or variants thereof, are capable of binding to B cell surface markers under conditions effective to collectively or individually induce apoptosis of the contacted B cell. Consequently, the methods and products of the present invention can be used therapeutically to treat, or as a preventative agent to protect against, a B cell-related condition or disorder.